Amber Vasold
Medical · Aberdeen, MDNPI 1013389683
Payments from drug & device makers
Across 489 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- AbbVie$1K
- Amgen$1K
- Pfizer$750
- GSK$727
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,109100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $1,190 |
| AstraZeneca | 60 | $1,174 |
| AbbVie(2 entities) | 81 | $1,147 |
| Amgen | 54 | $1,007 |
| Pfizer | 44 | $750 |
| GSK | 35 | $727 |
| Lilly USA, LLC | 38 | $713 |
| Johnson & Johnson | 15 | $320 |
| Amarin Pharma, Inc. | 11 | $234 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $214 |
| Silk Road Medical, Inc. | 1 | $178 |
| Exact Sciences | 8 | $176 |
| E.r. Squibb & Sons, L.L.C. | 10 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Merck | 8 | $147 |
| Bayer | 4 | $90 |
| Boehringer Ingelheim | 4 | $78 |
| Intuitive Surgical | 1 | $77 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Insulet Corporation | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Dexcom, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Mylan Specialty L.p. | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Greer Laboratories, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,109 in reported general payments places this provider in the 90th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 58 | $79,201 |
| OzempicSemaglutide | 45 | $77,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $61,649 |
| EliquisApixaban | 28 | $46,226 |
| JardianceEmpagliflozin | 21 | $34,928 |
| FarxigaDapagliflozin Propanediol | 30 | $31,839 |
| RybelsusSemaglutide | 12 | $18,484 |
| VascepaIcosapent Ethyl | 16 | $12,813 |
| MounjaroTirzepatide | 12 | $12,779 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,698 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,443 |
| Praluent PenAlirocumab | 15 | $8,924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 144 | $6,525 |
| BelsomraSuvorexant | 11 | $4,742 |
| Gabapentin | 147 | $4,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,190 | $95,63357 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $713 | $91,97970 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $727 | $80,790101 claims |
| PfizerEliquis | $750 | $46,22628 claims |
| Boehringer IngelheimJardiance | $78 | $34,92821 claims |
| AstraZenecaFarxiga, Symbicort | $1,174 | $34,76543 claims |
| MerckBelsomra | $147 | $4,74211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 medical providers in Maryland.
Other medical in Aberdeen
- Nicholas WunderAberdeen$40K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
- Megan PayneLutherville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.